Plain-English translation of NCT06027788 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study compares two approaches during heart valve surgery: using a new device called the CardioGard Embolic Protection Cannula, which is designed to protect your brain and organs from debris during surgery, versus using a standard cannula (tube). Researchers want to see if the protective device reduces serious complications like stroke, delirium, and kidney injury that can happen after valve surgery.
Patients undergoing heart valve surgery face risks of stroke, confusion after surgery, and kidney problems. This trial exists to find out whether the new protective device can prevent these complications and keep patients safer during and after surgery.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the new CardioGard protective device or standard care during your scheduled valve surgery. After surgery, you will be followed up for 12 months with visits and assessments to monitor your recovery and watch for complications. The study enrollment period runs for about 30 months, and all participants will be tracked for one year after their procedure to evaluate how well the protective device works.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States